0IV3.L
GERON CORP GERON ORD SHS
£1.25
-1.19%
2026-05-29
About GERON CORP GERON ORD SHS
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Key Fundamentals
EPS (TTM)
£-0.36
ROE
-27.1%
Revenue Growth (YoY)
30.9%
Profit Margin
-34.3%
Debt/Equity
53.28
Price/Book
3.50
Beta
0.68
Market Cap
£260.5M
Avg Volume (10D)
45K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
£1.85
60D Low
£1.21
Avg Volume
30K
Latest Close
£1.25
Get breakout alerts for 0IV3.L
Sign up for Breakout Scanner to receive daily notifications when 0IV3.L triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
GERON CORP GERON ORD SHS (0IV3.L) is listed on the London Stock Exchange (LSE). Breakout Scanner monitors 0IV3.L daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups.. Data is provided for informational purposes only and does not constitute financial advice.